Last $2.68 USD
Change Today +0.10 / 3.88%
Volume 49.9K
FCSC On Other Exchanges
Symbol
Exchange
NASDAQ CM
As of 8:10 PM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

fibrocell science inc (FCSC) Snapshot

Open
$2.60
Previous Close
$2.58
Day High
$2.68
Day Low
$2.50
52 Week High
03/14/14 - $6.30
52 Week Low
12/15/14 - $2.28
Market Cap
109.5M
Average Volume 10 Days
80.5K
EPS TTM
$-0.72
Shares Outstanding
40.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for FIBROCELL SCIENCE INC (FCSC)

fibrocell science inc (FCSC) Related Bloomberg News

View More Bloomberg News

fibrocell science inc (FCSC) Related Businessweek News

No Related Businessweek News Found

fibrocell science inc (FCSC) Details

Fibrocell Science, Inc., an autologous cell therapy company, focuses on developing various treatments for skin diseases and conditions with unmet medical needs. The company, through its proprietary autologous fibroblast technology, Fibrocell, develops biologic solutions and medical applications of azficel-T for restrictive burn scarring and vocal cord scarring conditions; and biologic products for patients with rare genetic skin and tissue disorders. It has collaboration agreements with Intrexon Corporation for using genetically-modified fibroblasts for treating rare and serious skin, and connective tissue diseases; and University of California, Los Angeles to focus on skin-derived stem cells and other ways to convert skin cells to other cell types. The company was formerly known as Isolagen, Inc. and changed its name to Fibrocell Science, Inc. in September 2009. Fibrocell Science, Inc. was founded in 1995 and is headquartered in Exton, Pennsylvania.

58 Employees
Last Reported Date: 06/2/14
Founded in 1995

fibrocell science inc (FCSC) Top Compensated Officers

Chairman of the Board, Chief Executive Office...
Total Annual Compensation: $454.8K
Vice President of Human Resources and Busines...
Total Annual Compensation: $199.4K
Vice President of Scientific Affairs
Total Annual Compensation: $188.0K
Vice President of Quality
Total Annual Compensation: $148.8K
Executive Vice President of Marketing
Total Annual Compensation: $250.0K
Compensation as of Fiscal Year 2013.

fibrocell science inc (FCSC) Key Developments

Fibrocell Science, Inc. Announces IND Allowed to Proceed to Develop New Treatment for Wounded Warrior Amputees to Prevent Stump Skin Diseases

Fibrocell Science, Inc. announced the U.S. Food and Drug Administration is allowing the company's investigational new drug (IND) application to proceed for developing a new treatment for amputee stump skin to prevent skin diseases that lead to prosthesis abandonment. By using autologous fibroblasts to help wounded warrior amputees, Fibrocell aims to address skin breakdown and pain at the stump site by promoting the skin properties found on the palms and soles. Specifically, autologous volar fibroblasts will be used to re-program non-palmar/plantar skin to develop a thickened stratum corneum and express keratin-9. If successful, this technique should reduce the rate of prosthesis abandonment in wounded warriors and other people with amputations. To support development of this program, Fibrocell has collaborated with Lt. Col. Jon Meyerle, MD, of the Uniformed Services University of the Health Sciences in submission of an invited application to the Peer Reviewed Orthopaedic Research Program Clinical Trial Award (DoD/CDMRP/PRORP) Grant. This program is administered by the Congressionally Directed Medical Research Programs Office of the Department of Defense. Fibrocell would begin the program upon receipt of the grant.

Fibrocell Science, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

Fibrocell Science, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company’s revenue from product sales were $20,000 against $68,000 a year ago. Operating loss was $6,191,000 against $13,121,000 a year ago. Loss from continuing operations before income taxes was $6,012,000 against $6,601,000 a year ago. Loss from continuing operations, net of tax was $6,012,000 or $0.17 diluted per share against $6,601,000 or $0.31 diluted per share a year ago. Net loss was $6,012,000 or $0.17 diluted per share against $6,605,000 or $0.31 diluted per share a year ago. For the nine months, the company’s revenue from product sales were $124,000 against $156,000 a year ago. Operating loss was $23,787,000 against $24,839,000 a year ago. Loss from continuing operations before income taxes was $22,278,000 against $25,799,000 a year ago. Loss from continuing operations, net of tax was $22,278,000 or $0.60 diluted per share against $25,799,000 or $1.04 diluted per share a year ago. Net loss was $22,278,000 or $0.60 diluted per share against $25,812,000 or $1.04 diluted per share a year ago. Net cash used in operating activities was $15,512,000 against $16,039,000 a year ago.

Fibrocell Science, Inc. to Report Q3, 2014 Results on Nov 07, 2014

Fibrocell Science, Inc. announced that they will report Q3, 2014 results on Nov 07, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
FCSC:US $2.68 USD +0.10

FCSC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioTime Inc $3.33 USD -0.13
Bluebird Bio Inc $92.00 USD +1.02
Organovo Holdings Inc $7.24 USD +0.50
Sangamo BioSciences Inc $15.36 USD -0.36
Vertex Pharmaceuticals Inc $118.90 USD +1.16
View Industry Companies
 

Industry Analysis

FCSC

Industry Average

Valuation FCSC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 651.8x
Price/Book 3.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 388.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact FIBROCELL SCIENCE INC, please visit www.fibrocellscience.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.